Oxamniquine supplier | CasNO.21738-42-1

Name
OXAMNIQUINE(200MG)DISCONTINUED
EINECS
CAS No. 21738-42-1
Density 1.174g/cm³
Solubility
Melting Point 147-149°
Formula C14H21 N3 O3
Boiling Point 443.6°Cat760mmHg
Molecular Weight 279.339
Flash Point 222.1°C
Transport Information
Appearance
Safety Poison by ingestion, intraperitoneal and intramuscular routes. Human mutation data reported. An antischistosomal agent. When heated to decomposition it emits toxic fumes of NO_x.
Risk Codes
Molecular Structure
Hazard Symbols
Synonyms 6-Quinolinemethanol,1,2,3,4-tetrahydro-2-[(isopropylamino)methyl]-7-nitro- (8CI); (?à)-Oxamniquine;1,2,3,4-Tetrahydro-6-(hydroxymethyl)-2-[(isopropylamino)methyl]-7-nitroquinoline;6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline;Mansil; NSC 352888; Oxamniquine; UK 4261; UK 4271; Vansil
PSA 90.11000
LogP 2.86390

Oxamniquine Chemical Properties

Empirical Formula: C₁₄H₂₁N₃O₃
Molecular Weight: 279.3348 g/mol
EINECS: 244-556-4
Index of Refraction: 1.56
Density: 1.174 g/cm³
Flash Point: 222.1 °C
Enthalpy of Vaporization: 73.91 kJ/mol
Boiling Point: 443.6 °C at 760 mmHg
Vapour Pressure: 1.19E-08 mmHg at 25 °C
Structure of Oxamniquine (CAS NO.21738-42-1):

IUPAC Name of Oxamniquine (CAS NO.21738-42-1): [7-Nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol

Oxamniquine Uses

Oxamniquine (CAS NO.21738-42-1) is used for treatment of schistosomiasis and is equally effective as praziquantel for treating S. mansoni infections.

Oxamniquine Toxicity Data With Reference

1.	mmo-sat 364 nmol/plate	JPETAB Journal of Pharmacology and Experimental Therapeutics. 200 (1977),1.
2.	msc-ham:lng 1 µmol/L	MUREAV Mutation Research. 157 (1985),1.
3.	orl-rat LD50:30 mg/kg	DDREDK Drug Development Research. 4 (1984),229.
4.	ipr-rat LD50:20 mg/kg	DDREDK Drug Development Research. 4 (1984),229.
5.	ims-rat LD50:60 mg/kg	DDREDK Drug Development Research. 4 (1984),229.
6.	orl-mus LD50:1300 mg/kg	ARZNAD Arzneimittel-Forschung. Drug Research. 31 (1981),555.
7.	ipr-mus LD50:650 mg/kg	DDREDK Drug Development Research. 4 (1984),229.
8.	orl-rbt LD50:500 mg/kg	DDREDK Drug Development Research. 4 (1984),229.
9.	orl-ham LD50:950 mg/kg	DDREDK Drug Development Research. 4 (1984),229.

Oxamniquine Consensus Reports

EPA Genetic Toxicology Program.

Oxamniquine Safety Profile

Poison by ingestion, intraperitoneal and intramuscular routes. Human mutation data reported. An antischistosomal agent. When heated to decomposition it emits toxic fumes of NO_x.

Oxamniquine Specification

Oxamniquine ,its cas register number is 21738-42-1. It also can be called 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-((isopropylamino)methyl)-7-nitro- ; 1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol ; and {2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydro-6-quinolinyl}methanol . It causes worms to shift from the mesenteric veins to the liver where the male worms are retained and is a potent single-dose agent for treatment of Schistosoma mansoni infection in man. It is generally well tolerated following oral doses. Oxamniquine (CAS NO.21738-42-1) is extensively metabolised to inactive metabolites which are excreted in the urine, and is a semisynthetic tetrahydroquinoline and possibly acts by DNA binding resulting in contraction and paralysis of the worms and eventual detachment from terminal venules in the mesentry and death.

Product Name

OXAMNIQUINE(200MG)DISCONTINUED